Comparing SG&A Expenses: TG Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and Amneal Pharmaceuticals, Inc. over the past decade.

Key Insights

From 2014 to 2023, Amneal Pharmaceuticals consistently outpaced TG Therapeutics in SG&A spending, with a peak in 2023 reaching approximately 430 million USD. This represents a staggering 400% increase from their 2014 figures. In contrast, TG Therapeutics saw a more modest rise, with their expenses peaking in 2021 at around 152 million USD, marking a 520% increase from 2014.

Strategic Implications

These trends highlight differing strategic priorities. Amneal's higher SG&A expenses suggest aggressive market expansion and operational scaling, while TG Therapeutics' growth indicates a focus on strategic investments in key areas. Understanding these dynamics can provide investors and stakeholders with valuable insights into each company's market positioning and future potential.